Author

Muhanad Hreh

Institution: University of Minnesota

Observed institutions: University of Minnesota, Mayo Clinic

OpenAlex ID: A5031947846

Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience

2015 · Muhanad Hreh, Darci Zblewski, et al. · Blood · 5

Traveling treatment: medical tourism in the emerging era of potentially transmissible therapeutics

2017 · Muhanad Hreh, Claudia S. Cohn, et al. · Transfusion · 4

Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy

2016 · Salih Subari, Firas Baidoun, et al. · International Journal of Hematology

Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival

2015 · Hassan B Alkhateeb, Muhanad Hreh, et al. · Blood

Effect of prior hypomethylating agent (HMA) use on clinical outcome of patients (Pts) with secondary acute myeloid leukemia (sAML) arising from myelodysplastic syndrome (MDS) when treated with standard induction chemotherapy (7+3).

2015 · Salih Subari, Firas Baidoun, et al. · Journal of Clinical Oncology

Works count: 5

Citation count: 9

H-index: 2

I10-index: